• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种水果和根部提取物的专利混合物(WS 1541)对大鼠和人类细胞前列腺增生及炎症的影响。

Effects of a proprietary mixture of extracts from fruits and roots (WS 1541) on prostate hyperplasia and inflammation in rats and human cells.

作者信息

Sens-Albert Carla, Weisenburger Sabrina, König Beatrix C, Melcher Silas F, Scheyhing Ulrike A M, Rollet Karin, Lluel Philippe, Koch Egon, Lehner Martin D, Michel Martin C

机构信息

Preclinical R&D, Dr. Willmar Schwabe GmbH and Co., KG, Karlsruhe, Germany.

Urosphere SAS, Parc Technologique Du Canal, Toulouse, France.

出版信息

Front Pharmacol. 2024 Mar 15;15:1379456. doi: 10.3389/fphar.2024.1379456. eCollection 2024.

DOI:10.3389/fphar.2024.1379456
PMID:38560358
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10979176/
Abstract

Phytotherapeutics, particularly extracts from (saw palmetto) fruit or (stinging nettle) root, are popular for the treatment of male lower urinary symptoms in many countries, but their mechanism of action is poorly understood. We performed and studies to obtain deeper insight into the mechanism of action of WS 1541, a proprietary combination of a fruit and an root extract (WS 1473 and WS 1031, respectively) and its components. We used the sulpiride model of benign prostatic hyperplasia in rats and tested three doses of WS 1541 in comparison to finasteride, evaluating weight of prostate and its individual lobes as well as aspects of inflammation, oxidative stress, growth and hyperplasia. In human BPH-1 cells, we studied the effect of WS 1473, WS 1031, WS 1541 and finasteride on apoptosis, cell cycle progression and migrative capacity of the cells. WS 1541 did not reduce prostate size in sulpiride treated rats but attenuated the sulpiride-induced changes in expression of most analyzed genes and of oxidized proteins and abrogated the epithelial thickening. , WS 1473 and WS 1031 showed distinct profiles of favorable effects in BPH-1 cells including anti-oxidative, anti-proliferative and pro-apoptotic effects, as well as inhibiting epithelial-mesenchymal-transition. This data supports a beneficial effect of the clinically used WS 1541 for the treatment of lower urinary tract symptoms associated with mild to moderate benign prostate syndrome and provides a scientific rationale for the combination of its components WS 1473 and WS 1031.

摘要

植物疗法,尤其是来自锯叶棕果实或荨麻根的提取物,在许多国家都常用于治疗男性下尿路症状,但其作用机制尚不清楚。我们进行了体内和体外研究,以更深入地了解WS 1541(一种锯叶棕果实和荨麻根提取物(分别为WS 1473和WS 1031)的专利组合)及其成分的作用机制。我们使用大鼠良性前列腺增生的舒必利模型,并与非那雄胺相比测试了三种剂量的WS 1541,评估前列腺及其各个叶的重量以及炎症、氧化应激、生长和增生等方面。在人BPH-1细胞中,我们研究了WS 1473、WS 1031、WS 1541和非那雄胺对细胞凋亡、细胞周期进程和细胞迁移能力的影响。WS 1541在舒必利治疗的大鼠中并未减小前列腺大小,但减弱了舒必利诱导的大多数分析基因和氧化蛋白表达的变化,并消除了上皮增厚。此外,WS 1473和WS 1031在BPH-1细胞中显示出不同的有利作用,包括抗氧化、抗增殖和促凋亡作用,以及抑制上皮-间质转化。这些数据支持临床使用的WS 1541对治疗与轻度至中度良性前列腺综合征相关的下尿路症状具有有益作用,并为其成分WS 1473和WS 1031的组合提供了科学依据。

相似文献

1
Effects of a proprietary mixture of extracts from fruits and roots (WS 1541) on prostate hyperplasia and inflammation in rats and human cells.一种水果和根部提取物的专利混合物(WS 1541)对大鼠和人类细胞前列腺增生及炎症的影响。
Front Pharmacol. 2024 Mar 15;15:1379456. doi: 10.3389/fphar.2024.1379456. eCollection 2024.
2
Combined and Extracts (WS 1541) Exert Anti-proliferative and Anti-inflammatory Effects in a Mouse Model of Benign Prostate Hyperplasia.组合提取物(WS 1541)在良性前列腺增生小鼠模型中发挥抗增殖和抗炎作用。
Front Pharmacol. 2019 Mar 29;10:311. doi: 10.3389/fphar.2019.00311. eCollection 2019.
3
Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms.锯叶棕(锯齿棕)果实提取物和荨麻(异株荨麻)根提取物:良性前列腺增生及相关下尿路症状医学治疗中的可行替代方案。
Planta Med. 2001 Aug;67(6):489-500. doi: 10.1055/s-2001-16496.
4
WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH.在与良性前列腺增生相关的下尿路症状患者中使用 WS PRO 160 I 120毫克(锯叶棕和荨麻提取物的组合)。
Ther Adv Urol. 2019 Oct 11;11:1756287219879533. doi: 10.1177/1756287219879533. eCollection 2019 Jan-Dec.
5
Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.锯叶棕与荨麻提取物联合用药与非那雄胺治疗良性前列腺增生症男性患者的比较:前列腺体积及治疗效果分析
BJU Int. 2000 Sep;86(4):439-42. doi: 10.1046/j.1464-410x.2000.00776.x.
6
Effects of algerian nettle ( L.) on benign prostatic hyperplasia and their mechanism of action elucidation: in vivo and in silico approaches.阿尔及利亚荨麻(L.)对良性前列腺增生的影响及其作用机制的阐明:体内和体外方法。
Nat Prod Res. 2024 Nov;38(22):4017-4027. doi: 10.1080/14786419.2023.2272283. Epub 2023 Oct 22.
7
Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms--long-term follow-up of a placebo-controlled, double-blind, multicenter trial.锯叶棕和荨麻提取物联合用药治疗下尿路症状的疗效与安全性——一项安慰剂对照、双盲、多中心试验的长期随访
Int Urol Nephrol. 2007;39(4):1137-46. doi: 10.1007/s11255-006-9173-7. Epub 2007 Feb 15.
8
Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial.锯叶棕和荨麻提取物联合用药治疗下尿路症状的长期疗效和安全性——一项安慰剂对照、双盲、多中心试验
World J Urol. 2005 Jun;23(2):139-46. doi: 10.1007/s00345-005-0501-9. Epub 2005 Jun 1.
9
Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer.营养保健品对良性前列腺增生和前列腺癌的治疗与预防
Arch Ital Urol Androl. 2019 Oct 2;91(3). doi: 10.4081/aiua.2019.3.139.
10
[Treatment of benign prostatic hyperplasia. Results of a treatment study with the phytogenic combination of Sabal extract WS 1473 and Urtica extract WS 1031 in urologic specialty practices].
Fortschr Med. 1995 Jan 30;113(3):37-40.

引用本文的文献

1
Project-Based Public-Private Collaborations.基于项目的公私合作。
Handb Exp Pharmacol. 2024;286:21-31. doi: 10.1007/164_2024_722.

本文引用的文献

1
Cell Plasticity in a Mouse Model of Benign Prostate Hyperplasia Drives Amplification of Androgen-Independent Epithelial Cell Populations Sensitive to Antioxidant Therapy.良性前列腺增生小鼠模型中的细胞可塑性驱动对抗氧化治疗敏感的雄激素非依赖性上皮细胞群体的扩增。
Am J Pathol. 2024 Jan;194(1):30-51. doi: 10.1016/j.ajpath.2023.09.010. Epub 2023 Oct 10.
2
[Conservative and pharmacological treatment of benign prostatic hyperplasia : The German S2e-guideline 2023-part2].[良性前列腺增生的保守及药物治疗:2023年德国S2e指南 - 第二部分]
Urologie. 2023 Oct;62(10):1048-1056. doi: 10.1007/s00120-023-02183-5. Epub 2023 Oct 5.
3
Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders.
当前和新兴的尿失禁及相关疾病的药理学靶点和治疗方法。
Pharmacol Rev. 2023 Jul;75(4):554-674. doi: 10.1124/pharmrev.121.000523. Epub 2023 Mar 14.
4
Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research-The ConPhyMP-Guidelines.药理学和毒理学研究中提取物化学表征的最佳实践——ConPhyMP指南。
Front Pharmacol. 2022 Sep 13;13:953205. doi: 10.3389/fphar.2022.953205. eCollection 2022.
5
The EQIPD framework for rigor in the design, conduct, analysis and documentation of animal experiments.用于动物实验设计、实施、分析和记录的严格性的EQIPD框架。
Nat Methods. 2022 Nov;19(11):1334-1337. doi: 10.1038/s41592-022-01615-y.
6
Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals.对涉及实验动物的临床前生物医学实验设计、实施及分析中内部有效性指南的系统评价。
BMJ Open Sci. 2020 Apr 15;4(1):e100046. doi: 10.1136/bmjos-2019-100046. eCollection 2020.
7
Treatment of Benign Prostatic Hyperplasia by Natural Drugs.天然药物治疗良性前列腺增生。
Molecules. 2021 Nov 25;26(23):7141. doi: 10.3390/molecules26237141.
8
Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-β family.上皮细胞可塑性、上皮-间充质转化和 TGF-β 家族。
Dev Cell. 2021 Mar 22;56(6):726-746. doi: 10.1016/j.devcel.2021.02.028.
9
and Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH).固定联合治疗:良性前列腺增生症(BPH)治疗的体外验证。
Int J Mol Sci. 2020 Dec 2;21(23):9178. doi: 10.3390/ijms21239178.
10
Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.炎症是治疗与良性前列腺增生相关的下尿路症状的医学靶点。
World J Urol. 2020 Nov;38(11):2771-2779. doi: 10.1007/s00345-020-03106-1. Epub 2020 Feb 14.